Ocugen is trading at $0.83, down 5.31%, as its decline coincides with a broad market-wide sell-off and a 5.19% drop in biotech-sector XBI.
- On November 5, 2026, the Nasdaq and S&P 500 were also reported sharply lower.
- Ocugen’s Q3 results were released November 4; revenue beat estimates, and its adjusted loss matched expectations.
- Shares had risen 17.35% that session, so prior-day earnings news does not clearly explain this session’s decline.